Covered recipient · General Payments record
WENDY W PARRISH
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2021–2024
$1,594.71
- Reported across 55 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $396.73 | 15 |
| Education | $99.00 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $169.17 | 4 |
| Astellas Pharma US Inc | $120.47 | 2 |
| ABIOMED | $43.23 | 1 |
| Lilly USA, LLC | $36.56 | 2 |
| Otsuka America Pharmaceutical, Inc. | $34.60 | 2 |
| Exact Sciences Corporation | $28.00 | 2 |
| Phadia US Inc. | $22.72 | 1 |
| Amgen Inc. | $22.18 | 1 |
| PFIZER INC. | $18.80 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABIOMED | $43.23 | 07/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142305551 | CMS |
| Amgen Inc. | $22.18 | 07/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117649410 | CMS |
| Astellas Pharma US Inc | $99.00 | 02/14/2024 | Education | Undisputed | 01/23/2026 | 1139504271 | CMS |
| Astellas Pharma US Inc | $21.47 | 08/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139530930 | CMS |
| Exact Sciences Corporation | $14.30 | 04/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1128383434 | CMS |
| Exact Sciences Corporation | $13.70 | 08/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1128383438 | CMS |
| Lilly USA, LLC | $18.80 | 03/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135993326 | CMS |
| Lilly USA, LLC | $17.76 | 06/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135989718 | CMS |
| Novo Nordisk Inc | $125.00 | 03/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108573807 | CMS |
| Novo Nordisk Inc | $20.58 | 03/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108567893 | CMS |
| Novo Nordisk Inc | $5.80 | 04/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108570962 | CMS |
| Novo Nordisk Inc | $17.79 | 10/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108567659 | CMS |
| Otsuka America Pharmaceutical, Inc. | $17.83 | 01/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1119158265 | CMS |
| Otsuka America Pharmaceutical, Inc. | $16.77 | 04/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1119158267 | CMS |
| PFIZER INC. | $18.80 | 09/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131945206 | CMS |
| Phadia US Inc. | $22.72 | 03/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1067587882 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.